Radiology Professionals Radiology Professionals
    Magazines     eNews      Latest News     Job Board     Conferences & Education     Featured Q&As     Post Your Resume     Break Room
New subscriber?
Free Subscription

SIGN IN
Username:
Password: [Lost?]

Login to manage your
subscriptions & profile




Radiology Conferences, Events, and Education

Radiology Conferences &
Educational Opportunities

More Events


Related Terms:
radiology , sonography , MRI , CT , imaging , diagnostic imaging , X-ray , Xray , dosemetry , interventional radiology , ARRT
InterMune Receives European Union Approval for Esbriet® (pirfenidone) | NEWS-Line for Respiratory Care Professionals
03/03/2011
NEWSRoom | Source:  

InterMune Receives European Union Approval for Esbriet® (pirfenidone)



InterMune, Inc. announced that the European Commission (EC) has granted marketing authorization for Esbriet® (pirfenidone). Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. The approval authorizes marketing of Esbriet in all 27 EU member states, and marks a significant turning point for the treatment of IPF patients in Europe. More than 100,000 patients suffer from IPF in the 10 nations that comprise the most-populated European countries; approximately 87,000 patients in the five largest countries of Germany, France, Spain, Italy and the United Kingdom.

“InterMune is proud to bring the first IPF medicine, Esbriet, to patients in Europe,” said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. “We are very pleased with our approved label for Esbriet and believe it will effectively support the access, pricing, reimbursement and marketing of Esbriet in Europe. The approval of Esbriet not only marks an historic moment in the treatment of IPF patients, but also an exciting new chapter for our company as we now transition to become an international commercial organization. Our seasoned leadership team in the EU is working very diligently to make Esbriet available to European patients as soon as possible, beginning with Germany in September of this year.”

Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch Esbriet in the so-called “Top 5” EU countries as follows: Germany in September of 2011; France, Spain and Italy in the first half of 2012 and in the United Kingdom in mid-2012. InterMune also plans to launch Esbriet in all or substantially all of the 10 most important pharmaceutical markets in the EU by approximately mid-2012.

Roland du Bois, MD, Professor of Respiratory Medicine, Imperial College, London, and co-chair of the Esbriet Phase 3 clinical program, said, “IPF is a chronic, progressive, respiratory disease with an estimated survival rate of only 20% after five years, which makes it more lethal than many cancers, and yet no therapeutic interventions have been approved for European patients suffering from this devastating disease—until today. The approval of this new medicine for European patients is a landmark event in IPF care, as Esbriet now offers individuals suffering from this appalling disease a novel treatment that has been shown to have a clinically meaningful effect in their disease.”




Share This!






Short Link: http://www.news-line.com/?s368950
Copy




comments powered by Disqus


Healthcare Jobs

Healthcare Jobs

Operating Roon Nurses
Illinois Sports Medicine & Orthopedic Surgery Center
Morton Grove, Illinois

Hospice Patient Care Manager
Mercy Medical Center
Daphne, Alabama

Licensed Nursing Assistants
Presidential Oaks
Concord, NH

Medical Laboratory Technologist
Ohio State University Wexner Medical Center
Columbus, Ohio

Mlt/Mt/Mls
Black Hills Pediatrics
Rapid City, South Dakota

Nurse Practitioner
Central West Healthcare
St Louis, Missouri

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.

HOME | GENERAL INFORMATION | READER SERVICES | ADVERTISER SERVICES | RSS DIRECTORY | CONTACT US
Copyright ©2014 NEWS-Line Publishing